Study of B/F/TAF in Participants Switching From CAB + RPV to B/F/TAF for HIV-1 Infection (EMPOWER)

PHASE4CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

December 13, 2023

Primary Completion Date

January 29, 2025

Study Completion Date

April 23, 2025

Conditions
HIV-1-infection
Interventions
DRUG

B/F/TAF

Tablets administered without regard to food

Trial Locations (18)

32806

Bliss Health, Orlando

33075

CHU Bordeaux - Hopital Saint-Andre, Bordeaux

34982

Midway Immunology and Research Center, Ft. Pierce

45100

CHR Orleans, Orléans

46202

Indiana University Infectious Diseases Research, Indianapolis

74374

Centre Hospitalier Annecy Genevois, Pringy

89106

Las Vegas Research Center, Las Vegas

92103

UC San Diego AntiViral Research Center (AVRC), San Diego

92262

BIOS Clinical Research, Palm Springs

93301

Franco Felizarta, MD, Bakersfield

99202

MultiCare Rockwood Main Clinic, Spokane

02118

Boston Medical Center, Boston

07102

Saint Michael's Medical Center, Newark

L8L2X2

Hamilton Health Sciences-SIS Clinic, Hamilton

M5B 1W8

St. Michael's Hospital, Toronto

M5G 2C4

University Health Network - Toronto General Hospital, Toronto

Unknown

APHM - Hospital Sainte Marguerite, Marseille

HU de Strasbourg - Nouvel Hopital Civil, Strasbourg

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Gilead Sciences

INDUSTRY